$2.63 0.02 (+0.77%)
11/6/2009 4:00 PM

EXACT Sciences Corp (EXAS)

CAPS Rating: 5 out of 5

An applied genomics company that develops proprietary DNA-based technologies for use in the detection of cancer.

Current Price $2.63 Mkt Cap $93.22M
Open $2.65 P/E Ratio 0.00
Prev. Close $2.61 Div. (Yield) N/A (N/A)
Daily Range $2.53 - $2.65 Volume 27,471
52-Wk Range $0.22 - $3.15 Avg. Daily Vol. 41,000

EXAS News and Commentary

Caps

This ticker is not currently Ratable.

Add Stock to Watchlist

All Members

36 Outperform
0 Underperform
 

All-Star Members

14 Outperform
0 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top EXAS Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Troy2008 (99.47)
Submitted September 14, 2009

I would have started this pitch earlier as I bought thousands of shares at .34 cents but EXAS just became available on Caps with a new 100 million market cap.
With new management in place Exact Sciences will be entering FDA trials with a DNA… More

7 Comments | Reply | Report this Post

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

EXAS VS S&P 500 (SPY)

Fools bullish on EXAS are also bullish on:

Recent Community Commentary

Read the most recent pitches from members about EXAS.

Recs

0
Member Avatar proisback (26.41) Submitted: 9/23/2009 6:19:31 PM : Outperform Start Price: $2.88 EXAS Score: -9.36

There are currently no analysts covering EXAS, but in a few months there will be BUY recs by a few sell side analysts. These BUY recs will bring in institutional buyers which will drive the stock price up dramatically. There will be new health legislation that will pay for routine screening without co-pays. EXAS is developing the best non invasive FDA approved test now. The time to BUY is before the large institutions hear about EXAS from the sell side analysts.

Report this Post 0 Comments | Reply | Permalink

Recs

2
Member Avatar theonlypro4U (< 20) Submitted: 9/23/2009 2:56:00 PM : Outperform Start Price: $2.89 EXAS Score: -8.58

New management has great credentials from past success, and sell side analysts will pick up coverage in the next few months with strong buys. New health legislation will push prevention, and pay for tens of millions of Americans to get free screening for diseases that can be prevented such as Colon cancer. EXAS will get FDA approval for the best non invasive way to screen for Colon cancer. The shares are under the radar screen now but that will change once analysts publish buy recs. Now is the time for retail investors to purchase for rapid appreciation over the next few months, and for years to come.

Report this Post 0 Comments | Reply | Permalink

Recs

2
Member Avatar chas1232123 (< 20) Submitted: 9/23/2009 10:02:22 AM : Outperform Start Price: $2.91 EXAS Score: -9.70

I believe EXAS is greatly undervalued, and will appreciate stongly over the next several years, probably with strong gains from here within a few months. An unexpected reversal of FDA policy a couple of years ago, compounded by terrible general market conditions and management not up to the challenge, combined to drive it way down despite exclusive long term control of very strong technology for a huge, underserved market (colon cancer screening). The negative factors that drove it down have been effectively dealt with, and the primary remaining obstacle is for the market to learn about it. As new management makes more details of their plans public over the next few months, I expect price to appreciate strongly.

Report this Post 0 Comments | Reply | Permalink
View All 10 Pitches »

Leaderboard

Find the members with the highest scoring picks in EXAS.

Score Leader

zzlangerhans

zzlangerhans (99.36) Score: +54.35

Even a stopped clock is right twice a day, and true to the form I came close to nailing the high and the low. But I can't get back in unless EXAS gets pumped to 4 again. Thanks for nothing CAPS!

Top
Pick 		Member Name Member
Rating 		Start
Date 		Call Time
Frame 		Start
Price 		Stock
Gain 		S&P
Gain 		Score Commentary
alberta911 83.70 9/29/2009 Outperform 5Y $2.80 -6.07% +0.58% -6.65
theonlypro4U < 20 9/23/2009 Outperform 3M $2.89 -9.00% -0.42% -8.58 1 Comment
martiantrader2 82.55 9/23/2009 Outperform 5Y $2.89 -9.00% +0.23% -9.23
proisback 26.41 9/24/2009 Outperform 3M $2.88 -8.68% +0.68% -9.36 1 Comment
chas1232123 < 20 9/23/2009 Outperform 3Y $2.91 -9.62% +0.08% -9.70 1 Comment
amyers1 70.48 9/22/2009 Outperform 1Y $2.91 -9.62% +0.18% -9.80
MichaelinWA 86.87 9/21/2009 Outperform 5Y $2.90 -9.31% +1.17% -10.48
liqu1d 81.29 9/24/2009 Outperform 5Y $2.88 -8.68% +2.08% -10.75
avscaptain 84.91 10/8/2007 Outperform 5Y $4.28 -38.54% -27.59% -10.95
richsimpson 97.72 10/22/2007 Outperform 5Y $4.18 -37.08% -24.99% -12.09
View Complete Scorecard »

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for EXAS.

Featured Broker Partners